Syfovre (pegcetacoplan)

Syfovre is covered only for geographic atrophy secondary to age-related macular degeneration (not GA from other causes) and only for the FDA‑approved indication, with authorization limited to 12 months. Coverage requires BCVA of ≥24 ETDRS letters (~20/320) documented, administration by or under supervision of an ophthalmologist, documentation of diagnosis and treatment plan, and dosing of 15 mg intravitreal injections to each affected eye every 25–60 days.

"Syfovre must be administered by or under the supervision of an ophthalmologist."

Sign up to see full coverage criteria, indications, and limitations.